Nicotine replacement therapy
- there is evidence that NRT doubles the smoking cessation rate compared with placebo
- NRT is less addictive than smoking
- NRT, unlike tobacco smoking, does not provide tar products and carbon monoxide
- currently, there is no evidence that nicotine causes cancer
- NRT provides nicotine in a slower and less satisfying way than tobacco smoking BUT is safer and much less addictive
- nicotine does have vascular effects and product licences require caution in patients with established vascular disease, especially after a recent event. However continuance of tobacco smoking doubles risk of recurrent events and mortality
- nicotine may cause nausea, dizziness, palpitations and headaches in patients who have not become tolerant to it
- NRT is not a magic cure but helps with withdrawal and craving symptoms
- use in pregnancy - see linked item
- the majority of NRT studies fail to follow up patients for more than a year. Therefore it is difficult to assess if health improvements achieved by NRT use are maintained long term
- a systematic review (4) regarding the use of NRT concluded:
- all of the commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) are effective as part of a strategy to promote smoking cessation
- NRT increases the odds of quitting approximately 1.5 to 2 fold regardless of setting
- effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the smoker -provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT
Notes:
- GPs have been able to prescribe nicotine replacement therapy products from 17 April 2001
- a systematic review of various pharmacotherapies for smoking cessation concluded that (2):
- varenicline, bupropion and the 5 nicotine replacement therapies were all more efficacious than placebo at promoting smoking abstinence at 6 and 12 months
Reference:
- (1) Drug and Therapeutics Bulletin 1999; 37(7): 52-56.
- (2) British Heart Foundation, Factfile 6/99.
- (3) MeReC Bulletin 1999, 10 (3): 9-12.
- (4) Silagy C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; (3):CD000146
- (5) Eisenberg MJ et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008 Jul 15;179(2):135-44
Related pages
- Formulations used in nicotine replacement therapy
- Stopping smoking (evidence-based guidance)
- Nicotine replacement therapy (NRT) and pregnancy
- Bupropion
- Varenicline
- NICE guidance - use of nicotine replacement therapy (NRT), cytisinicline, varenicline and bupropion for smoking cessation
- NRT and ischaemic heart disease (IHD)
- Smoking (cigarette smoking equivalences to cigar smoking and roll-ups)
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.